In cases with a high level of CD8+ T cell tumor infiltration, the PFS of patients treated with atezolizumab + bevacizumab combination therapy was significantly extended, and the response rate was also significantly improved compared with cases with low levels. The gene discussed is CD8A; the disease is neoplasm.